The impact of cytomegalovirus (CMV) serostatus (seropositive [ + ] or seronegative [ 2 ] ) of the donor (D) and recipient (R) on mortality after allogeneic non-T cell-depleted stem cell transplantation (SCT) in the era of preemptive therapy was assessed among 1750 patients by means of multivariable Cox regression models. In an analysis that included only pre-SCT variables, D + /R + and D + /R 2 patients had the highest risk for mortality. After neutropenia or the occurrence of CMV disease was controlled for, only D + /R 2 patients remained at a significantly higher risk for mortality. Mortality due to bacteremia or invasive fungal infection was higher among D + /R 2 (18.3%) than D 2 /R 2 (9.7%) patients (P , .001). Thus, CMV serostatus remains associated with mortality; neutropenia due to ganciclovir administration and CMV disease explain the association with mortality among seropositive recipients. However, in D + /R 2 subjects, mortality appears to be associated with bacterial and fungal infection, indicating a possible immunomodulatory effect of primary CMV infection that was undetected despite intensive monitoring.
The role of cytomegalovirus (CMV) infection in the immunocompromised host has evoked a significant body of work since the agent and its disease manifestations were first described in the 1960s [1] . Distinguishing asymptomatic from clinically significant infection has been at the core of the debate about the relationship between CMV infection, disease, and mortality for decades. In the 1970s and 1980s, studies indicated that CMV infection of tissues, such as the lung or gut, was associated with significant morbidity and mortality in the immunocompromised host, with the stem cell transplant recipient most susceptible to its effects [2] . The amelioration of CMV disease with effective antivirals in certain clinical situations appears to have solidified these observations. However, recent data suggest that subclinical CMV infection (i.e., CMV infection without clinically definable invasive disease) may also be a factor in the morbidity and mortality seen in the immunocompromised host. In subjects with human immunodeficiency virus (HIV) infection or AIDS, studies have demonstrated that CMV load is an independent predictor of death, even when HIV load is taken into account [3] . Primary CMV infection is an independent risk factor for graft rejection and allograft loss after solid organ transplantation [4] ; antiviral prophylaxis attenuates these effects in both renal [5] and heart [6] transplant recipients. Finally, CMV serostatus has been identified as an independent risk factor for overall mortality after liver transplantation [7] .
Before the use of antiviral prophylaxis or preemptive therapy, CMV serostatus was identified as a potent predictor of both CMV disease and death after stem cell transplantation (SCT) as well [8] [9] [10] . Studies published in the early 1980s revealed that the incidence of CMV infection and disease varied from 42% to 69% and from 16% to 25%, respectively, in seropositive patients after allogeneic marrow transplantation [8, 11, 12] . Since the 1990s, the direct effects of CMV infection (e.g., CMV pneumonitis and gastrointestinal disease) early after transplantation have been dramatically reduced with the use of preemptive or prophylactic antiviral therapy [13] [14] [15] [16] [17] [18] [19] . Ganciclovir prophylaxis, however, is associated with a high incidence of neutropenia, which leads to more invasive bacterial and fungal infections [14, 17, 20] . Furthermore, ganciclovir prophylaxis may blunt the recovery of CMV-specific immune responses [21] , which may contribute to an increased risk for CMV disease late after transplantation [17] . Ganciclovir's beneficial effects on CMV infection and disease are, thus, balanced by its toxicity, and its use as prophylaxis has not been associated with consistent improvements in overall survival [13, 14, 17, 19, 22] .
As a result, many transplantation centers have adopted a preemptive strategy, whereby antivirals are administered only to patients with evidence of active viral replication (as evidenced by such tests as the pp65 antigenemia assay). This strategy shortens the course of ganciclovir therapy and also spares those patients who do not develop antigenemia the toxicity of ganciclovir. Among seropositive patients at our center, the use of this approach has decreased the cumulative incidence of CMV disease to 3.5%-10% by day 100 after transplantation and has been associated with a lower incidence of invasive fungal infection, compared with use of ganciclovir therapy at engraftment [18, 23] . Given these advances, we hypothesized that CMV serostatus would no longer be associated with mortality in the era of preemptive ganciclovir therapy. We thus sought to test this hypothesis in a large cohort of non-T cell-depleted stem cell transplant recipients, while controlling for other variables known to be associated with overall survival.
Patients and Methods
Patients. Patients who underwent their first allogeneic SCT between 1 April 1992 and 30 September 1998 were eligible for inclusion in this observational cohort; recipients of T cell-depleted transplants or those who underwent adoptive immunotherapy against CMV were excluded from analysis. Of the 1760 patients who met these entry criteria, 10 were missing either donor or recipient CMV serology data, leaving 1750 patients available for analysis. Patients in the cohort were followed up until death or last contact; all living patients had >2 years of clinical follow-up. Conditioning for SCT [24] [25] [26] and prophylaxis against graft-versus-host disease (GVHD) [27, 28] were done as described in those reports.
Supportive care. Supportive care was standardized by protocol throughout the study. CMV-seronegative patients received seronegative or leukoreduced (residual white blood cell count ,5 £ 10 6 cells per product) blood products. Patients who were seropositive for herpes simplex virus received acyclovir (250 mg/m 2 intravenously [iv]) twice daily, from the start of conditioning until day 30 after SCT or the resolution of chemotherapy-induced mucositis, whichever occurred first. Antifungal prophylaxis with fluconazole (400 mg iv or orally daily) was provided from the start of conditioning until day 75 after SCT [29] . Patients with chemotherapy-induced neutropenia received ceftazidime (2 g iv 3 times daily) for bacterial prophylaxis, and amphotericin B was added to treat fever persisting for .3 days or to treat a suspected fungal infection. One doublestrength tablet of trimethoprim-sulfamethoxazole was provided twice weekly after engraftment for the prevention of Pneumocystis carinii pneumonia [30] . Patients with chronic GVHD received 1 double-strength tablet of trimethoprim-sulfamethoxazole daily or daily penicillin with intermittent trimethoprim-sulfamethoxazole for the prevention of infection due to encapsulated bacteria [31] . All patients received food with a low microbial count until discharge from the hospital; patients with severe mucositis received parenteral alimentation.
Preemptive therapy for CMV infection. All patients were monitored weekly from engraftment until day 100 after SCT for CMV reactivation (CMV-seropositive recipients) or primary infection (CMV-seronegative recipients) by use of the pp65 antigenemia assay and culture of blood, as described elsewhere [32] . Ganciclovir therapy was started on the day of the first positive antigenemia test result for all patients without neutropenia at an induction dose of 5 mg/kg iv every 12 h for 1 week and then was continued as maintenance therapy at 5 mg/kg once daily for 5-6 days each week. A subset of CMV-seropositive patients in this cohort received prophylactic ganciclovir as part of a randomized trial [17] . Foscarnet was used for patients with neutropenia (absolute neutrophil count [ANC] ,750/mL) or at the discretion of the treating physician; induction doses were 60 mg/kg iv every 12 h, with maintenance at 90 mg/kg once daily for 5-6 days each week. Preemptive antiviral therapy was continued until day 100 after SCT. Dose reductions for reduced renal function were made on the basis of calculated creatinine clearance, according to adjusted ideal body weight.
Acute and chronic GVHD. Acute and chronic GVHD were diagnosed and graded according to consensus criteria [33] . The occurrence of chronic GVHD was evaluated among all patients who survived in remission >100 days after SCT. Primary treatment of GVHD was with corticosteroids and was done as described elsewhere [27] .
Data sources. Clinical, laboratory, pharmacologic, pathologic, and microbiologic data were retrieved from a prospectively entered, integrated database. Information in the computer database is complete for the first 100 days after SCT, after which patients are discharged from the Fred Hutchinson Cancer Research Center system. Patient clinical records after discharge are maintained in a long-term follow-up database, which includes prospectively entered data from a 1-year follow-up examination and review, yearly questionnaires sent to local physicians and patients, and copies of hospital discharge summaries, death certificates, and autopsy reports. For this study, the computer database was examined to determine outcome (including the date of death) for all patients. Additional information extracted from these records included the development of relapse and chronic GVHD. To determine conditions present at death, chart reviews were done by a physician who was unaware of patient serostatus. This information was extracted from death certificates, discharge summaries, and autopsy reports, when available.
Definitions. Underlying disease risk was classified as advanced for all patients not in remission, patients with acute nonlymphocytic leukemia in second or later remission, and patients with acute lymphocytic leukemia in third remission or later. Patients with chronic myelogenous leukemia were classified as having advanced disease when in blast crisis at time of SCT. Patients with multiple myeloma, refractory anemia with excess blasts, or refractory anemia with excess blasts in transition were also classified as having advanced disease. All other patients were classified as not having advanced disease. Engraftment was defined as the date on which 2 consecutive measurements of the ANC were .750 cells/mL. The occurrence of postengraftment neutropenia was defined as 2 consecutive ANC measurements ,750 cells/mL after the occurrence of engraftment, as defined above. ANC failure was defined as either initial failure to engraft (as defined above) or the occurrence of postengraftment neutropenia.
CMV disease was defined as the demonstration of CMV by biopsy specimen from visceral sites (by culture or histology) or the detection of CMV by culture or direct fluorescent antibody stain in bronchoalveolar lavage fluid in the presence of new or changing pulmonary infiltrates [34] . Death attributable to bacterial infection was defined as death within 2 weeks of a positive result of blood culture for a significant pathogen (excluding coagulase-negative staphylococci and diphtheroids) or, in patients with invasive end-organ disease, within 6 weeks of culture documentation. Death attributable to fungal infection was defined as death occurring within 2 weeks of candidemia or, in patients with end-organ disease (e.g., invasive aspergillosis), within 6 weeks of culture documentation. All deaths that occurred after relapse of underlying disease (i.e., those with a diagnosis of recurrent malignancy after achieving remission after SCT) were coded as death due to relapse.
Statistical analysis. Cox proportional hazards regression models were fitted to examine the association of CMV serostatus of the patient and donor (seropositive
) with the time-to-event outcome mortality. The following additional pre-SCT variables were included in the analysis of prognostic factors: patient and donor sex, patient and donor age, underlying disease, disease risk, patient herpes simplex virus serostatus, patient varicellazoster virus serostatus, preparative regimen, GVHD prophylaxis regimen, donor type, source of stem cells, cell dose, and year of SCT. Because the purpose of this study was not to investigate the factors associated with overall mortality, the association of these potential confounders with mortality is not presented. Rather, the association of CMV serostatus with mortality was calculated, after adjustment for these variables. All P values from the regression models are 2-sided and were calculated from the Wald test. No adjustments were made for multiple comparisons.
A second model was constructed to include the influence of post-SCT variables, including GVHD, ANC failure, CMV disease, and virus load, as determined by the maximum number of pp65 antigenstaining cells per slide. For this purpose, any positive result for antigenemia and .10 cells/slide were modeled as time-dependent covariates on overall survival. Postengraftment acute and chronic extensive GVHD and CMV disease were also modeled as timedependent covariates on overall survival. Time zero for these regression models was taken as the date of SCT, and the data were treated as being left-truncated so that a patient did not enter the risk set until time of first positive antigenemia test, onset of CMV disease, or onset of GVHD.
Results
In total, 1750 consecutive stem cell transplant recipients were evaluated. Patient characteristics are shown in table 1. Of the 1750 patients, 1566 (89.5%) received non-T cell-depleted bone marrow transplants and 161 (9.2%) received non-T celldepleted peripheral blood stem cell transplants. Most patients underwent SCT for acute leukemia (37.5%) or chronic myelogenous leukemia (34.7%) and had advanced disease (57%). More than half (57.2%) received their allograft from a mismatched or unrelated donor. The majority of patients underwent conditioning with cyclophosphamide and total body irradiation (53.7%) and received cyclosporine and methotrexate as prophylaxis against GVHD (84% figure  2A ). Because CMV antigenemia triggered the use of preemptive ganciclovir therapy in our study (and ganciclovir is associated with a high risk for neutropenia), we first assessed whether the occurrence of antigenemia was associated with mortality, after controlling for the pre-SCT factors mentioned above (including CMV serostatus). The addition of CMV antigenemia as a timedependent covariate on the hazard for overall mortality did not change the association of CMV serostatus with mortality (data not shown). Of interest, if pp65 antigenemia was analyzed as a time-dependent covariate for the hazard of overall mortality among D + /R 2 patients alone, the risk was somewhat lower for patients who developed antigenemia than for those who did not (HR, 0.7; 95% CI, 0.3-1.5). These data suggest that the use of ganciclovir in the D + /R 2 cohort (along with its associated toxicity) is unlikely to be a factor in the relationship.
Because CMV load is associated with poor outcome in the setting of solid organ transplantation, we next sought to determine whether high virus load accounted for the observed differences in mortality. As shown in figure 2B , the cumulative incidence of high virus load (as determined by a maximum antigenemia level of .10 cells/slide) was higher among seropositive than among seronegative stem cell transplant recipients. When high virus load was added to the model, however, the association between D + /R + serostatus and mortality was somewhat attenuated (table 3) , whereas the association between D + /R 2 serostatus and mortality was unchanged.
Adjustment for CMV disease, GVHD, and ANC failure. The cumulative incidence of CMV disease over the entire period of follow-up was higher among CMV-seropositive (D + /R + , 17.6%; D 2 /R + , 20.9%) than CMV-seronegative (D + /R 2 , 5.3%; D 2 /R 2 , 1.1%) transplant recipients. When CMV disease was analyzed as a time-dependent covariate to determine its contribution to the relationship between CMV serostatus and mortality, the HR was further attenuated among D + /R + patients, whereas the relationship among D + /R 2 patients remained relatively unchanged (table 3 ). The addition of acute or chronic GVHD to the model did not affect the association between CMV serostatus and mortality (data not shown). The incidence of site-specific GVHD of the gut (a possible portal of entry for invasive bacterial and fungal pathogens) was similar among the 4 serogroup pairs and did not explain the differences in mortality (data not shown). . When the occurrence of ANC failure was analyzed to determine its contribution to the relationship between CMV serostatus and mortality, the HR was again attenuated among CMV-seropositive patients, whereas the relationship among D + /R 2 patients remained relatively unchanged (table 3) . Together, these analyses indicate that the association between R + serostatus and mortality is primarily explained by CMV disease, neutropenia, and virus load; these factors do not, however, totally explain the association between D + /R 2 serostatus and all-cause mortality.
Cause-of-death analysis. Because CMV disease and neutropenia failed to explain the increased mortality seen in D + /R 2 patients, we next assessed the cause of death for those patients who died within 1 year after SCT, focusing on the D + /R 2 and the D 2 /R 2 cohorts of patients. In this analysis, the incidence of death due to relapse, severe GVHD leading to organ failure, or treatment-related toxicity was similar in the 2 groups (table 4). The combined incidence of mortality due to bacterial and fungal infection, however, was significantly higher in the D + /R 2 cohort than in the D 2 /R 2 cohort (18.3% vs. 9.7%; P , :001).
A separate analysis of the cumulative incidence of significant bloodstream infections during the first 100 days after SCT showed similar findings: The incidence of gram-negative or significant gram-positive bacteremia (excluding diphtheroids and coagulase-negative staphylococci) was significantly higher among D + /R 2 patients than among D 2 /R 2 patients (48.4% vs. 33.7%; P , :001).
Discussion
In this study, we have shown that CMV serostatus continues to be associated with mortality after allogeneic SCT, despite the use of preemptive and prophylactic ganciclovir therapy. Of interest, our results indicate that CMV-seronegative recipients of stem cells from seropositive donors (D + /R 2 ) are at the highest risk for overall mortality among all serogroup pairs. Furthermore, although the influence of serostatus on mortality among CMV-seropositive stem cell transplant recipients appears to be explained by neutropenia, virus load, and CMV disease, these factors do not account for the mortality disadvantage seen among the D + /R 2 group. Rather, these patients appear to die of invasive bacterial and fungal infections at a rate greater than that of their D 2 /R 2 counterparts. The higher incidence did not appear to be related to ganciclovir toxicity, because controlling for the occurrence of neutropenia failed to explain the association between D + /R 2 serostatus and overall mortality. Furthermore, D + / R 2 patients who received ganciclovir for CMV antigenemia showed a trend toward lower mortality, compared with those who did not receive ganciclovir. We thus hypothesize that these results suggest the indirect influence of abortive CMV infections in this cohort, with attendant immunosuppression. The important strengths of our study include the use of a prospectively compiled, integrated database that included longterm follow-up; this allowed us to determine conditions present at death with high veracity. Perhaps most important, all patients received protocol-driven care that included prophylaxis against opportunistic infections, as currently recommended by consensus guidelines [31] . Supportive care also included the provision of CMV-seronegative or filtered blood products to our seronegative stem cell transplant recipients [35] , a strategy that limited primary CMV infection to 12% among the D + /R 2 cohort. The majority of CMV transmission is thus thought to have occurred via the CMV-seropositive allograft. To account for any further differences in care, we also controlled for year of SCT in our model. Thus, we believe that our findings are not due to temporal trends in the care of patients; rather, they represent true estimates of the associations among serostatus, invasive infections, and mortality after SCT.
Theindirecteffects ofCMVinfectioninthestemcell transplant recipient have recently received increased scrutiny. In the preganciclovir era, the direct effects of CMV infection and disease were so substantial (and largely unpreventable) that subtle immunosuppressive effects could not be demonstrated. In the current era of preemptive therapy, ganciclovir-induced neutropenia and its attendant risks for invasive fungal and bacterial infection haveprecluded analysisoftheseindirecteffects ofCMVinfection [20] . However, a recent study of seropositive patients receiving T cell-depleted allogeneic transplants revealed a significant increase in transplant-related morbidity and mortality, compared withthoseamongD 2 /R 2 patients,despitethehighlyeffectiveprevention of CMV disease by preemptive therapy [36] . Infectious causes of death, including an impressive 28% mortality due to pulmonary infection, accounted for the differences in mortality. Althoughganciclovir-inducedneutropeniawascommon,itfailed to completely explain the mortality difference [36] . Craddock et al. [37] recently presented similar findings in the unrelated T cell-depleted setting: CMV seropositivity in stem cell transplant recipients was associated with a 2-fold increase in mortality, althoughCMVdiseasewasonlypartiallyexplanatory.CMVseronegativity may also be protective among recipients of non-T cell-depleted transplants from unrelated donors. In a multivariable analysis, McGlave et al. [38] showed that recipient CMV seronegativity was associated with a significant reduction in mortality. Of note, however, supportive care in this study was not standardized across the 85 transplantation centers. Most importantly, perhaps, all 3 studies analyzed the contribution of patient and donor serostatus separately or considered D + /R 2 patients together with CMV-seropositive recipients when computing risk estimates. Thus, the unique association between D + / R 2 serostatus and mortality was not captured.
To explore the causes of transplant-related mortality in the present study, we analyzed the records of D + /R 2 and D 2 /R 2 patients who died within 1 year after SCT. In our analysis, cumulative mortality at 1 year after SCT was significantly higher among D + /R 2 patients than among D 2 /R 2 patients (table 4); this mortality difference was explained by bacterial and fungal infection. The presence of pp65 antigenemia and thus the receipt of ganciclovir therapy, however, did not correlate with the development of these infectious complications; indeed, D + /R 2 patients who received ganciclovir therapy for pp65 antigenemia had a somewhat lower incidence of mortality. Of importance (and in contrast to findings among T cell-depleted transplant recipients [36] ), these inferior outcomes did not appear to be accounted for by GVHD, because the inclusion of acute or chronic GVHD into the multivariable model did not significantly alter the association seen between CMV serostatus and survival. These data suggest that preemptive ganciclovir therapy given for pp65 antigenemia could be protective against invasive bacterial and fungal infections in the D + /R 2 setting. We thus hypothesize that primary CMV infection and its immunomodulatory effects may commonly occur in the absence of preceding antigenemia.
Abortive, subclinical CMV infections in the SCT setting have been amply documented. Polymerase chain reaction (PCR) testing for CMV DNA appears to be considerably more sensitive than the pp65 antigenemia assay for detecting evidence of systemic CMV infection and thus provides a potential window into the effects of subclinical CMV infection. Gor et al. [39] recently published a longitudinal study of CMV load, as detected by quantitative competitive PCR, in stem cell transplant recipients, most of whom were seropositive before SCT. In that study, virus load strongly correlated with CMV disease. Rapid increases in disease risk occurred only for virus loads .3.8 log 10 genomes/mL, however; as such, the positive predictive value of 3 log 10 genomes/mL for CMV disease was only 37% (vs. 86% for virus loads .5 log 10 genomes/mL). Thus, a high proportion of patients with lower virus loads did not progress directly to disease, even in the absence of preemptive therapy. The outcomes for these patients PCR-positive for CMV were not specified. In 1991, de Gast et al. [40] demonstrated that abortive primary CMV infections also occur in D + /R 2 SCT patients. In this study, 12 D + /R 2 patients were monitored weekly by viral culture, pp65 antigenemia, and PCR for CMV DNA. Remarkably, 4 patients developed transient pp65 antigenemia and DNAemia without progression to viremia, seroconversion, or CMV disease, despite the fact that none received anti-CMV therapy. Again, outcomes for these patients were not disclosed. In our retrospective study, we were not able to assess the incidence of subclinical PCR positivity for CMV DNA. Our study suggests, however, that episodes of abortive infection may, indeed, be associated with consequences, namely, a higher risk for invasive bacterial and fungal infections.
Primary CMV infection (as occurs commonly in the D + /R 2 setting) has long been associated with an increase in the net state of immunosuppression after solid organ transplantation, with attendant increases in the incidence of bacterial and fungal infections. Until recently, however, the effect of primary infection on the incidence of invasive infections could not be easily separated from the effect of neutropenia attributed to its treatment with ganciclovir. CMV prophylaxis with valacyclovir (which does not cause neutropenia), however, decreases the incidence of both primary CMV infection and invasive bacterial infections in renal transplant recipients [5] , further defining the link between CMV infection and clinically significant immunomodulation in the solid organ transplant setting. Several potential mechanisms for CMV-induced immunosuppression have been identified. CMV simultaneously impairs the ability of lymphocytes and monocytes to produce and respond to cytokines, such as interleukin-1 and interleukin-2 [41] , and impairs the function of antigen-specific cytotoxic T lymphocytes and NK cells [42, 43] . CMV US2 destroys components of both the major histocompatibility complex (MHC) class I [44] and class II [45] pathways within macrophages and inhibits MHC class II expression on alveolar epithelial cells [46] , which dramatically impairs their primary role in antigen presentation. CMV infection of alveolar macrophages also inhibits the expression of surface or soluble CD14, which impairs responsiveness to gram-negative bacillary infections [47] . Studies have also demonstrated that CMV impairs the oxidative respiratory burst of macrophages [48, 49] ; furthermore, CMV infection may affect the macrophage's ability to perform phagocytosis effectively [48] . Endothelial cell injury by CMV [50] could also allow invasion across mucosal barriers in both the lung and the gastrointestinal tract, although, in our study, this potential mechanism was not mediated by documented gut GVHD. Finally, CMV infection may induce a deleterious immunologic shift toward Th2 responses in the lung [51] , which may predispose patients to invasive aspergillosis [52, 53] . The recent discovery of a viral interleukin-10 homologue produced by CMV [54, 55] makes these findings all the more intriguing. Any or all of these factors may play a role in the increased risk of subsequent bacterial and fungal infections after primary CMV infection.
Our results have several important implications. First, the preferential use of stem cells from CMV-seronegative donors for CMV-seronegative recipients should be continued. Second, future analysis of the impact of CMV serostatus on treatmentrelated mortality should incorporate information on serogroup pairs, rather than considering D + /R 2 patients as equivalent to CMV-seropositive or to D 2 /R 2 stem cell transplant recipients. Finally, our data indicate that improved preemptive or prophylactic anti-cytomegalovirus strategies are required for the D + /R 2 cohort; these strategies could specifically target the prevention of invasive bacterial and fungal infections in this population. Ganciclovir or foscarnet prophylaxis could be considered in this setting, although this option is unpalatable, given the low incidence of primary CMV infection in these patients. More sensitive assays (such as PCR for CMV DNA) could be used to trigger preemptive therapy, but if abortive subclinical CMV infection (particularly within sites other than blood) causes significant immunomodulation in the absence of detectable CMV viremia, this strategy may fail to reduce the incidence of bacterial and fungal infections. b Hemolytic-uremic syndrome (9), pulmonary fibrosis (4), central nervous system hemorrhage (4), cardiac arrest/cardiomyopathy (4), or leukoencephalopathy (1).
Thus, the use of an antiviral with low toxicity (such as high-dose acyclovir or valacyclovir) as prophylaxis would be preferred. Indeed, prolonged high-dose acyclovir has already been documented to improve survival after allogeneic SCT [56] , although the mechanism that produces this benefit has not been clearly established. Therapy with non-myelosuppressive antivirals could thus be used as a probe to test the hypothesis that bacterial and fungal infections are caused by low-level CMV replication in the SCT setting.
